Molecular Partners AG (MOLN) stock

MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30

$3.01−0.08 (-2.59%)

Close on Nov 12, 2026Market cap $121.53MP/E –Yield –

Molecular Partners total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Molecular Partners has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Molecular Partners's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MOLN.

Revenue growth-100.0% · median -38.4%

Advertisement
300 × 250

See a number that looks wrong?